Clinical trial
IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia…
NCT00469144 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00469144 |
|---|---|
| Title | IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome |
| Official title | A Randomized Study of Once Daily IV Busulfan With Fludarabine With Hemopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome, Leukemia, Acute Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Busulfan, Fludarabine |
| Enrollment | 233 |
| Start date | Jun 1, 2005 |
| Primary completion | Nov 1, 2014 |
| Completion | Nov 1, 2014 |
| First posted | May 4, 2007 |
| Last update posted | Jan 19, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: